ArticleCancer cell2014

ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.

Scott C Bresler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.